This research project focuses on developing a next-generation precision oncology platform that identifies patient-specific tumor vulnerabilities using functional genomics rather than relying solely on genomic mutations. By integrating genome-scale CRISPR screening with drug repurposing strategies, the approach systematically uncovers critical tumor dependencies in aggressive cancers such as triple-negative breast cancer and directly links them to existing FDA-approved therapies. These findings are validated in patient-derived models, enabling the rapid translation of functional insights into personalized treatment strategies. Ultimately, this work aims to shift cancer therapy from mutation-based selection to dependency-driven precision medicine, improving clinical outcomes while accelerating the delivery of effective, tailored treatments to patients.
